NCT07218510
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07218510
Title Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial
Acronym LonGEVity
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors City of Hope Medical Center
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.